[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastric-adenocarcinoma-and-gastroesophageal-junction-adenocarcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastric-adenocarcinoma-and-gastroesophageal-junction-adenocarcinoma":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,39,62,92,131],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100645007","phase-3-retlirafusp-alfa-injection-plus-chemotherapy-versus-investigators-choice-of-anti-pd-1-antibody-plus-chemotherapy-as-first-line-treatment-for-advanced-gastric-cancer-with-liver-metastases-100645007",false,"NCT07677293","Retlirafusp Alfa Injection Plus Chemotherapy Versus Investigator's Choice of Anti-PD-1 Antibody Plus Chemotherapy as First-line Treatment for Advanced Gastric Cancer With Liver Metastases","Retlirafusp Alfa Injection Plus Chemotherapy Versus Investigator's Choice of Anti-PD-1 Antibody Plus Chemotherapy for Previously Untreated, Advanced Gastric or Gastroesophageal Junction Cancer With Liver Metastases: a Randomized, Controlled, Multicenter Phase III Clinical Study","Inclusion Criteria:\n\n* 1\\. Age ≥ 18 years; 2. Patients with recurrent or previously untreated advanced gastric or gastroesophageal junction cancer with liver metastases, histopathologically confirmed as adenocarcinoma.\n\n  3\\. No prior systemic therapy (including anti-HER2 therapy) for advanced or metastatic GC\u002FGEJC. Patients who have received prior adjuvant or neoadjuvant therapy are eligible provided that the time from completion of last therapy to first recurrence or disease progression is \\> 6 months.\n\n  4\\. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. 5. At least one evaluable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n\n  6\\. Adequate organ and bone marrow function. 7. Female subjects of non-childbearing potential are defined as those who are postmenopausal, or have undergone documented hysterectomy and\u002For bilateral oophorectomy. Male subjects and female subjects of childbearing potential must agree to use at least one medically approved contraceptive method during the study and for 120 days after the last dose of study treatment. A serum pregnancy test must be negative within 3 days prior to the start of study treatment, and subjects must not be breastfeeding.\n\n  8\\. Voluntarily signed informed consent, and willing and able to comply with scheduled visits, study treatment, laboratory tests, and other study procedures.\n\nExclusion Criteria:\n\n* 1\\. Known gastric cancer of squamous cell carcinoma, undifferentiated carcinoma, or other histological types, or adenocarcinoma mixed with other histological types.\n\n  2\\. Untreated or inadequately treated central nervous system (CNS) metastases, or uncontrolled or symptomatic active CNS metastases.\n\n  3\\. Diagnosis of any other malignancy within 5 years prior to study entry, except for: skin basal cell carcinoma or squamous cell carcinoma that has been locally treated and documented as cured, superficial bladder cancer, cervical carcinoma in situ, breast ductal carcinoma in situ, papillary thyroid carcinoma, and other early-stage tumors with low risk of recurrence that have undergone curative treatment as judged by the investigator.\n\n  4\\. Presence of any active, known, or suspected autoimmune disease. 5. Prior treatment with TGF-β inhibitors, anti-PD-1\u002FPD-L1 antibodies, anti-PD-L2 antibodies, anti-CD137 antibodies, CTLA-4 antibodies, or other drugs\u002Fantibodies targeting T-cell costimulatory or checkpoint pathways.\n\n  6\\. Severe, non-healing, or dehiscent wound, or active ulcer, or untreated fracture.\n\n  7\\. Any other serious physical or mental illness, or laboratory abnormalities that may increase the risk of study participation, interfere with study results, or render the subject unsuitable for the study judged by the investigator.","ALL","18 Years",{"count":19,"type":20},332,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This study is a randomized, controlled, open-label phase III clinical trial, aims to compare the efficacy and safety of Retlirafusp alfa injection plus CAPOX versus the investigator's choice of anti-PD-1 antibody plus CAPOX as first-line treatment in patients with advanced gastric cancer (GC) or gastroesophageal junction cancer (GEJC) with liver metastases",[26],"Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma","NOT_YET_RECRUITING","2026-06-24",{"date":30,"type":31},"2026-06-30","ACTUAL",{"date":33,"type":20},"2026-06-26",{"date":35,"type":20},"2028-12-31",{"name":37,"class":38},"Peking University","OTHER",{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":21,"phases":48,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":61},"100622485","phase-2-shr-1701-combined-with-chemotherapy-for-gastric-or-gastroesophageal-junction-adenocarcinoma-with-peritoneal-metastasis-100622485","NCT07384234","SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis","SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: A Randomized, Two-Cohort Study","Inclusion Criteria:\n\n1. Age ≥ 18 years old.\n2. Pathologically confirmed gastric or gastroesophageal junction adenocarcinoma (Siewert typeⅡ and type Ⅲ gastroesophageal junction adenocarcinoma are eligible for inclusion).\n3. Definitively diagnosed with peritoneal metastasis by exploratory laparoscopy and\u002Fperitoneal lavage cytology (CY0P1\u002FCY1P0\u002FCY1P1 are eligible, ovarian metastasis is permitted), and without gastric outlet obstruction or intestinal obstruction.\n4. No prior anti-tumor treatment history (including radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc.).\n5. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.\n6. Normal function of major organs.\n\nExclusion Criteria:\n\n1. Known HER2-positive.\n2. Previous history of gastric cancer surgery.\n3. Contraindications to surgical treatment or chemotherapy, or poor physical status and organ function precluding major abdominal surgery.\n4. Presence of distant metastases other than peritoneal metastases (e.g., liver, lung, ovarian, para-aortic lymph node, brain metastases, etc.).\n5. Active autoimmune disease within 4 weeks prior to enrollment or a history of autoimmune disease.\n6. Significant cardiovascular disease within 6 months prior to enrollment, including unstable angina or myocardial infarction.",{"count":47,"type":20},60,[49],"PHASE2","This study is a prospective, randomized, two-cohort trial designed to evaluate the efficacy and safety of two regimens in the treatment of gastric or gastroesophageal junction adenocarcinoma with peritoneal metastasis: SHR-1701 combined with intravenous and intraperitoneal paclitaxel plus S-1, or SHR-1701 combined with CAPOX.",[26],"2026-01-26",{"date":54,"type":31},"2026-02-03",{"date":56,"type":20},"2026-01-31",{"date":58,"type":20},"2030-12-30",{"name":60,"class":38},"Ruijin Hospital",2,{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":21,"phases":72,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":91},"100590032","phase-2-phase-ii-rainspot-zolbetuximab-paclitaxel-ramucirumab-for-cldn182-positive-gastro-esophageal-cancer-100590032","NCT06962137","Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer","Phase II RAINSPOT: a Multicentric Open Label Trial of Zolbetuximab-Paclitaxel-Ramucirumab in Second Line Setting for CLDN18.2 Positive Gastro-esophageal Adenocarcinoma","RAINSPOT","Inclusion Criteria:\n\n1. At least 18 years of age at the time of ICF\n2. WHO performance status 0 - 1\n3. Histologically proven metastatic gastroesophageal adenocarcinoma\n4. Pretreatment with one 1st line therapy according to SOC (+\u002F- immunotherapy)\n5. If relapse while adjuvant (immune\u002Fchemo) therapy or within 6 months ending adjuvant therapy the adjuvant therapy is considered a first line therapy\n6. CLDN18.2-positive (defined as ≥75% of tumour cells showing moderate-to-strong membranous CLDN18.2 staining, as determined by immunohistochemistry using the VENTANA CLDN18 \\[43-14A\\] RxDx Assay.\n7. Any PDL1 score\n8. Use of highly effective methods of birth control\n9. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.\n\nExclusion Criteria:\n\n\\- 1. Metastatic squamous cell cancer of the esophagus 2. Absolute contra-indication for anti-VEGF inhibitors (tumor perforation, active proteinuria, recent stroke, myocardial infarction, acute arterial thrombosis, active wound problem) 3. Other active malignancy 4. Pretreatment with Zolbetuximab or other anti-CLDN18.2 direct therapy in first line setting once available.\n\n5\\. Known hypersensitivity to the active substance Zolbetuximab or to any of the excipients \\[(Arginine, Phosphoric acid (E 338), Sucrose, Polysorbate 80 (E 433)\\] 6. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate, highly effective contraceptive 7. Participation in another interventional Trial with an investigational medicinal product (IMP) or device",{"count":71,"type":20},100,[49],"This study examines whether adding the drug Zolbetuximab to an existing treatment (Paclitaxel and Ramucirumab) can improve patients' survival. The goal is to see if this combination works better for patients whose tumours contain a specific protein (CLDN18.2). The results will be compared to past patient data from those who only received the standard treatment.\n\nZolbetuximab (Vyloy) is a cancer medicine that is used to treat adults with gastric or gastro-esophageal junction adenocarcinoma (a type of cancer of the stomach or the transition between the stomach and esophagus). Zolbetuximab will be administered via an intravenous infusion in combination with Paclitaxel and Ramucirumab (Cyramza) (two other cancer drugs that are the standard treatment for this condition). Treatment will take place at regular intervals in the hospital. In addition to treatment,patients will undergo a tumour biopsy. While the biopsy procedure may cause some discomfort or pain, it will only be performed if medically justifiable. Patients participation in the study will continue as long as they receive treatment and the disease does not worsen. The overall duration of the study, for all patients, will span several years.",[75,26],"Gastric Cancer Adenocarcinoma Metastatic",[77,78,79,80],"Zolbetuximab-Paclitaxel-Ramucirumab","second line","CLDN18.2 positive","gastro-esophageal adenocarcinoma","RECRUITING","2025-12-15",{"date":84,"type":31},"2025-12-22",{"date":86,"type":31},"2025-12-11",{"date":88,"type":20},"2030-08-30",{"name":90,"class":38},"Universitaire Ziekenhuizen KU Leuven",6,{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":99,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":100,"targetDuration":102,"studyType":103,"phases":4,"briefSummary":104,"conditions":105,"keywords":113,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":4},"100612988","augmented-response-of-volatile-biomarkers-in-the-assessment-of-oesophagogastric-cancer-aroma2-100612988","NCT07260734","AUGMENTED RESPONSE OF VOLATILE BIOMARKERS IN THE ASSESSMENT OF OESOPHAGOGASTRIC CANCER (AROMA2)","AROMA2","Inclusion Criteria:\n\n* Aged ≥ 18 years old.\n* Participants referred from primary care according to the urgent suspected cancer referral guidelines for potential underlying oesophagogastric cancer a for the reference test (described below).\n* Willing and able to provide informed written consent to take part in study.\n\nExclusion Criteria:\n\n* Previous oesophageal or gastric resection\n* History of cancer within three years (other than non-melanoma skin cancers)\n* Co-morbidities preventing breath collection\n* Pregnant participants\n* Allergies to any of the constituents of the nutrient drink including glucose, glycerol, iron sulphate, Maltodextrin (Corn, Potato), Xanthan Gum, Potassium Chloride, tyrosine, phenylalanine, and glutamic acid\n* Unable or unwilling to provide informed written consent.",true,{"count":101,"type":20},6000,"3 Months","OBSERVATIONAL","Cancer of the stomach and oesophagus is among the world's top five cancers. Survival rates are very poor as the disease presents late and early symptoms are non-specific. The study team has developed a non-invasive test for cancers of the stomach and oesophagus based on the detection of volatile organic compounds in exhaled breath. These compounds are known to be produced by both cancers as well as cancer associated bacteria within the gut.\n\nThe proposed innovation is to improve the accuracy of this test by investigating whether simple metabolic substrates can increase the production of these volatile organic compounds by both the tumour and its associated bacteria.",[106,107,26,108,109,110,111,112],"OESOPHAGO-GASTRIC CARCINOMA","Oesophageal Adenocarcinoma","Oesophageal Cancer Nos","Oesophageal Cancer","Oesophageal Junction Cancer","Breath Tests","Volatile Organic Compound",[114,115,116,117,118,119,120,121],"Oesophageal adenocarcinoma","Gastric adenocarcinoma","Breath testing","Microbiome","Augmentation","Volatile Organic Compounds","Volatilomics","Breathomics","2025-11-21",{"date":124,"type":31},"2025-12-03",{"date":126,"type":20},"2025-12-01",{"date":128,"type":20},"2028-11-01",{"name":130,"class":38},"Imperial College London",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":21,"phases":141,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":155},"100437899","phase-1-a-study-of-ak109-and-ak104-in-advanced-gastric-adenocarcinoma-or-gastroesophageal-junction-adenocarcinoma-100437899","NCT04982276","A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma","A Multicentre, Phase Ib\u002FII Clinical Study of AK109 and AK104 With or Without Chemotherapy in Second-line Treatment of Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma","Inclusion Criteria:\n\n1. Written and signed informed consent\n2. Age ≥ 18 years but ≤ 75 years\n3. ECOG of 0 or 1.\n4. Estimated life expectancy of ≥3 months.\n5. Histologically or cytologically documented advanced unresectable or metastatic gastric adenocarcinoma or gastroesophageal Junction (GEJ) adenocarcinoma.\n6. At least one measurable lesion per RECIST v1.1.\n7. Gastric adenocarcinoma or gastroesophageal junction (GEJ) adenocarcinoma with failure of first-line treatment with anti-PD-1\u002FL1 and chemotherapy\n8. Adequate organ function.\n9. Have agreed to take effective contraception from the date of signing the informed consent form until 120 days after the last administration.\n\nExclusion Criteria:\n\n1. Other invasive malignancies within 3 years, except for locally treatable (manifested as cured) malignancies, such as basal or skin squamous cell carcinoma, superficial bladder cancer, cervical or breast carcinoma in situ.\n2. Any previous systemic therapy targeting VEGF or anti-VEGFR signaling pathways.\n3. In addition to PD1 or PD-L1,Prior exposure to anti-CTLA-4 antibody, or any other antibody or drug therapy for T cell co-stimulatory or checkpoint pathways, such as ICOS or agonists (e.g. CD40, CD137, GITR and OX40 etc).\n4. Known history of primary immunodeficiency virus infection.\n5. Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.\n6. Known history of interstitial lung disease.\n7. Known history of active tuberculosis (TB).\n8. Central nervous system (CNS) metastasis, meningeal metastasis, spinal cord compression, or leptomeningeal disease.\n9. Patients with untreated chronic hepatitis B or HBV DNA exceeding 500IU\u002FmL or active hepatitis C should be excluded. Patients with HCV antibody positive are eligible to participate in the study if the results of HCV RNA test show negative.\n10. Known history of testing positive for human immunodeficiency virus (HIV).\n11. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage.\n12. Subjects with active, known or suspected autoimmune disease, or a medical history of autoimmune disease, with the exceptions of the following: vitiligo, alopecia, Grave disease, psoriasis or eczema not requiring systemic treatment within the last 2 years, hypothyroidism (caused by autoimmune thyroiditis) only requiring steady doses of hormone replacement therapy and type I diabetes only requiring steady doses of insulin replacement therapy, or completely relieved childhood asthma that requires no intervention in adulthood, or primary diseases that will not relapse unless triggered by external factors.\n13. Pregnant or lactating women.","75 Years",{"count":140,"type":20},138,[142,49],"PHASE1","This is a multicentre, Phase Ib\u002FII Clinical Study of AK109 and AK104 With or Without Chemotherapy in Second-line Treatment of Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma .",[26],"2025-11-17",{"date":147,"type":31},"2025-11-19",{"date":149,"type":31},"2021-08-23",{"date":151,"type":20},"2027-01-31",{"name":153,"class":154},"Akeso","INDUSTRY",1]